drugset / Trial / NCT04193553

Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

NCT04193553 ↗

Phase 2 Completed 77 enrolled Centre Leon Berard
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.

Timeline

Start
2020-01-17
Primary completion
2024-01-30
Completion
2024-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 24 mg —